US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

Analysis

What To Know: Lilly Cites Circ. Opinions In 340B Data Clash

By Dan McKay · June 2, 2026, 6:54 PM EDT

Pharmaceutical giant Eli Lilly & Co. cited two circuit opinions this week as it defended the legality of its threat to halt the flow of discounted drugs under the 340B pricing...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

Sanofi Aventis US LLC v. United States HHS, et al

Case Number

21-3167

Court

Appellate - 3rd Circuit

Nature of Suit

2899 APA Review/Appeal

Date Filed

November 26, 2021

Case Title

Novo Nordisk Inc, et al v. United States HHS, et al

Case Number

21-3168

Court

Appellate - 3rd Circuit

Nature of Suit

2899 APA Review/Appeal

Date Filed

November 26, 2021

Case Title

Novartis Pharmaceuticals Corporation v. Carole Johnson, et al

Case Number

21-5299

Court

Appellate - DC Circuit

Nature of Suit

2890 Other Statutory Actions

Date Filed

December 30, 2021

Case Title

AstraZeneca Pharmaceuticals LP v. Secretary United States Department of Health and H, et al

Case Number

22-1676

Court

Appellate - 3rd Circuit

Nature of Suit

2899 APA Review/Appeal

Date Filed

April 15, 2022

Recent Articles By Dan